Search results
Added:
2 months ago
Source:
Radcliffe CVRM
The human metabolome reflects a complex interplay of genetic and environmental factors. A large-scale analysis integrating blood metabolomic, genomic, and lifestyle data from ten prospective cohorts has identified a comprehensive profile of circulating metabolites that are associated with the future risk of developing type 2 diabetes (T2D).¹MethodologyResearchers conducted a pooled analysis of 23…
View more
ESC HF 2025 Late-Breaking Science Collection
Video Series
Added:
5 months ago
Source:
Radcliffe CVRM
A new real-world evidence study suggests that the incretin-based medicines tirzepatide and semaglutide have comparable cardiovascular (CV) benefits for patients with type 2 diabetes (T2D) and elevated CV risk.¹ While clinical trials have shown benefits for both drugs, the lack of direct head-to-head comparisons has left uncertainty regarding the optimal treatment choice in clinical practice.To…
View more
Added:
6 months ago
Source:
Radcliffe CVRM
The SURPASS-PEDS trial has found that tirzepatide significantly improved glycaemic control and reduced body mass index (BMI) in children and adolescents with type 2 diabetes (T2D) compared with placebo.¹ Youth-onset T2D presents unique challenges, as current treatments often show lower efficacy than in adults, and the disease course can be more aggressive.²Tirzepatide is a dual glucose-dependent…
View more
Added:
11 months ago
Source:
Radcliffe CVRM
AUTHOR: Greg GuilloryInterim findings from the Phase 3 ESSENCE trial (NCT04822181) published in the New England Journal of Medicine show that weekly treatment with semaglutide 2.4 mg significantly resolves metabolic dysfunction–associated steatohepatitis (MASH) and reduces liver fibrosis. At 72 weeks, semaglutide induced histological resolution of steatohepatitis in 62.9% of patients compared…
View more
Cardiovascular Risk in NAFLD
Added:
1 year ago
Review Article
Added:
5 months ago
Source:
Radcliffe CVRM
New findings from the IMPACT trial suggest that the GLP-1–glucagon dual receptor agonist, pemvidutide, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a condition with a high global prevalence and limited therapeutic options.¹˒²Pemvidutide is a dual receptor agonist that targets both the glucagon-like peptide-1 (GLP-1) and glucagon receptors, which are involved…
View more
View from the Thoraxcenter: What's Hot at AHA 24?
Added:
1 year ago
Podcast Episode
Added:
7 months ago
Source:
Radcliffe CVRM
Completing the National Health Service Diabetes Prevention Programme (NHS DPP) is associated with a lower incidence of not only type 2 diabetes (T2D) but also multiple other long-term conditions (LTCs), according to a new retrospective observational study published in Nature Medicine.¹This study analysed data from adults in England with non-diabetic hyperglycaemia (NDH) who were referred to the…
View more
SGLTi and GLP-1 in HF
Added:
11 months ago
Review Article